Dr. Lanza Recognized as a “Stem Cell Pioneer”
WORCESTER, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC) announced today that the company’s Chief Scientific Officer, Robert Lanza, MD, has been recognized by BioWorld, a widely-read publication covering the biotechnology industry, as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years. The story is included in the publication’s 20th anniversary issue.
The feature hails Dr. Lanza as a “stem cell pioneer,” and touches on some of his achievements at Advanced Cell Technology, including generating induced pluripotent stem (iPS) cells, as well as deriving retinal cells from human embryonic stem cells for the treatment of macular degeneration and Stargart’s disease, for which ACT filed its Investigational New Drug Application with the US Food and Drug Administration in November. Dr. Lanza is one of only six scientists to be honored, including Craig Venter, known for mapping the human genome. Other public figures recognized by the publication include Bill Gates, for his work in funding translational medical research and other projects through the Bill & Melinda Gates Foundation, and President Barack Obama, in recognition of his passage of healthcare reform legislation that provides for a pathway for regulatory approval of follow-on biologics.
“We are pleased that Dr. Lanza has been recognized for his contributions to the development of the stem cell industry, ,” commented William M. Caldwell IV, Chairman and CEO of ACT. “Dr. Lanza has long been a pioneer in advancing the role that human embryonic stem cells can play in treating diseases for which there is no suitable treatment, giving hope to millions who are suffering .”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2009.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
CEOcast, Inc. for Advanced Cell
Dan Schustack, 212-732-4300
Gotham Communications, LLC
Bill Douglass, 646-450-3615
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Stem Cells Health Biotechnology